Processa Pharmaceuticals, Inc. Tax Withholding Paid on Stock Awards
Processa Pharmaceuticals, Inc. (PCSA) reported Tax Withholding Paid on Stock Awards of $320 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-14
- Processa Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Processa Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $320.00, a 77.76% decline year-over-year.
- Processa Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Processa Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Processa Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $10.40K, a 34.57% decline from fiscal 2024.
- Processa Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $15.90K.
- Processa Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2022 was $88.84K, a 37.96% increase from fiscal 2021.
- Processa Pharmaceuticals, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2021 was $64.40K, a 32.37% decline from fiscal 2020.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $320.00 10-Q · filed 2026-08-14 | $320.00 derived: sum of 3 quarters · filed 2026-08-14 | $320.00 derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $320.00 10-Q · filed 2026-05-07 | $320.00 derived: sum of 2 quarters · filed 2026-05-07 | $320.00 derived: sum of 3 quarters · filed 2026-05-07 | $9.29K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $0.00 derived: sum of 2 quarters · filed 2026-03-18 | $8.96K derived: sum of 3 quarters · filed 2026-08-14 | $10.40K 10-K · filed 2026-03-18 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $8.96K derived: sum of 2 quarters · filed 2026-08-14 | $10.40K 10-Q · filed 2025-11-06 | $10.72K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $8.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $10.40K 10-Q · filed 2026-08-14 | $10.72K derived: sum of 3 quarters · filed 2026-08-14 | $14.37K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.44K 10-Q · filed 2026-05-07 | $1.75K derived: sum of 2 quarters · filed 2026-05-07 | $5.41K derived: sum of 3 quarters · filed 2026-05-07 | $7.42K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $312.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $3.97K derived: sum of 2 quarters · filed 2026-03-18 | $5.98K derived: sum of 3 quarters · filed 2026-03-18 | $15.90K 10-K · filed 2026-03-18 |
| 2024-09-30 | $3.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $5.67K derived: sum of 2 quarters · filed 2025-11-06 | $15.59K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $2.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $11.93K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $9.92K 10-Q · filed 2025-05-08 | |||
| 2022-12-31 | $53.60K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $88.84K 10-K · filed 2024-03-29 | ||
| 2022-09-30 | $35.25K 10-Q · filed 2022-11-08 | |||
| 2021-12-31 | $36.42K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $64.40K 10-K · filed 2023-03-30 | ||
| 2021-09-30 | $27.98K 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $95.21K 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |